You are here: Industry Insights > Ginkgo

News List

Optimvia, Ginkgo Bioworks to Manufacture Biosynthetic Heparin contractpharma
January 06, 2022
Optimvia to leverage Ginkgo's cell and enzyme engineering platform to improve the performance of Optimvia's biosynthetic heparin manufacturing technology.
Aldevron, Ginkgo Bioworks Partner on mRNA Vax Mfg. Breakthrough contractpharma
August 12, 2021
Achieved improvements in manufacturing yield of vaccinia capping enzyme (VCE), a component often required to produce mRNA therapies and vaccines.
Healthcare industry reported 90 deals worth $25.7 billion in May 2021 expresspharma
June 10, 2021
In May 2021, the healthcare industry reported 90 deals worth $25.7 billion as compared to the last 12-month average (May 2020 to April 2021) of101 deals worth $22.4 billion.
Biogen partners with Ginkgo Bioworks on gene therapy manufacturing platform pharmatimes
May 25, 2021
Biogen has entered into a new collaboration with Ginkgo Bioworks to develop a novel gene therapy manufacturing platform to ‘redefine the industry standard’ for manufacturing AAV-based vectors.